ONWARD Medical has raised more than €40 million in new capital through a private placement aimed at institutional investors, strengthening its balance sheet as it expands the commercial rollout of its neurostimulation technologies. The Netherlands-based company said the transaction generated gross proceeds of €40.6 million through the issuance of 13.5 million new ordinary shares priced at €3.00 each. The financing was announced on April 16, 2026, and marks a significant step for the Euronext-listed medtech group as it seeks to advance therapies for people living with spinal cord injuries and other movement-related disabilities.
Financing Details
A major portion of the fundraising came from EQT Life Sciences, which committed €25 million as part of the offering, while additional participation came from a mix of long-only and specialist healthcare investors. The company said the shares were placed through an accelerated bookbuild process, with pricing determined by its pricing committee. Settlement, delivery, and admission of the new shares to trading on Euronext Brussels, Amsterdam, and Paris are expected on April 20, 2026, subject to standard closing conditions.
Strategic Use of Proceeds
ONWARD Medical said the new funds, together with its existing cash resources, are expected to extend its financial runway into the first quarter of 2028, assuming it does not draw on its debt facility. Management indicated that the proceeds will primarily be directed toward advancing development programs, broadening commercial activities, strengthening operational infrastructure, and supporting general corporate needs. In practical terms, that means continued investment in clinical and regulatory work for the investigational ARC-IM platform, alongside a larger commercial push for the ARC-EX system in the United States, Europe, and selected international markets.
Commercial and Clinical Momentum
The financing comes as ONWARD Medical positions itself as a commercial-stage company, following market clearance of its ARC-EX system in both the United States and Europe. The company has framed investor support as a sign of confidence in the early uptake of that product and in the broader potential of its technology portfolio. At the same time, it is continuing to evaluate ARC-IM, an implantable system being studied for its ability to address blood pressure instability after spinal cord injury, including through the Empower BP pivotal trial.
Broader Company Profile
ONWARD Medical develops neurotechnology intended to restore movement, function, and independence for people affected by spinal cord injury and other neurological impairments. Its ARC Therapy platform is built on years of scientific research and has received 10 Breakthrough Device Designations from the U.S. Food and Drug Administration, reflecting the regulatory interest in its pipeline. Beyond its currently commercialized and investigational systems, the company is also working on approaches that combine implantable stimulation with brain-computer interfaces and artificial intelligence to enable thought-driven movement restoration.
Market Context and Governance
The company stated that the new shares will rank equally with existing ordinary shares once admitted to trading, preserving the rights attached to current equity. It also disclosed that EQT, the company itself, and certain board members have agreed to a 90-day lock-up period, subject to customary exceptions, which is often used to provide short-term market stability following an equity raise. Stifel Europe Securities acted as sole global coordinator on the transaction, while Stifel and Bank Degroof Petercam served as joint bookrunners.
This capital increase gives ONWARD Medical greater financial flexibility at a time when medtech companies are under pressure to show both commercial progress and clinical execution. By securing fresh funding from a recognized life sciences investor and a broader institutional base, the company has improved its ability to support product rollout while continuing to invest in next-generation platforms. The transaction therefore stands out not only as a financing event, but also as a signal that investors remain willing to back neurotechnology companies with a clearer path toward commercialization and longer-term clinical growth.